Tumor PD-L1 expression likewise influences treatment outcomes: patients with PD-L1 ≥ 50% experience shorter PFS (about 9.7 months vs. 26.5 months in those below 50%), and higher PD-L1 expression has been linked to worse PFS and OS [325,326,327,328,329,330]. The gene discussed is CD274; the disease is neoplasm.